Osborne Clarke advises RHYTHM AI on £2.15M seed financing round

Written on 10 September 2019

International legal practice Osborne Clarke has advised RHYTHM AI, a UK company focused on the treatment of Atrial Fibrillation (AF), on the closure of a £2.15m seed financing round. AF is the most common type of abnormal heart rhythm seen in clinical practice. It is associated with significant clinical morbidity and is also an independent risk factor for mortality.

The round was led by an affiliate of Rinkelberg Capital Ltd, a private wealth management firm based in London, and was supported by investment from founders.

Proceeds from the round will be used to fund multi-centre study of STAR Mapping to improve outcomes of persistent Atrial Fibrillation treatment. STAR Mapping™ is a new, AI driven mapping system developed by cardiologists at St Bartholomew’s Hospital London, using novel computer algorithms to identify the sources or drivers of AF.

Partner Matthew Edwards and Senior Associate Jonathan Falconer advised RHYTHM AI.

Osborne Clarke’s life science and healthcare sector team has a strong track record of providing highly sophisticated advice to biotech clients on cutting-edge issues, across multiple service lines.

Connect with one of our experts